NCCN Announces Funding for a Prostate Cancer Research Project | PR Newswire [Video]

The National Comprehensive Cancer Network’s Oncology Research Program’s grant will advance scientific knowledge of hematologic toxicity of PARPi in the treatment of patients with prostate cancer.

, /PRNewswire/ — The National Comprehensive Cancer Network^® (NCCN^®) Oncology Research Program (ORP) today announced funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi). The award is supported by Pfizer Global Medical Grants and Partnerships.

“This work will enhance our understanding of how to better care for individuals with prostate cancer.”

PARPi treatment is associated with hematologic toxicity, often leading to dose modification, treatment interruption, discontinuation, or the need for enhanced supportive care interventions. Anemia is the most common side effect associated with PARPi in patients with metastatic castration-resistant prostate cancer (mCRPC), with about a quarter of patients reporting serious anemia shortly after PARPi initiation. The use of PARPi is expected to …